Open Access. Powered by Scholars. Published by Universities.®

Econometrics Commons

Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences

Series

Articles 61 - 62 of 62

Full-Text Articles in Econometrics

Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns And Prognostic Factors For Survival, Ronald P. Dematteo, Jonathan J. Lewis, Denis H. Y. Leung, Salvinder S. Mudan, James M. Woodruff, Murray F. Brennan Jan 2000

Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns And Prognostic Factors For Survival, Ronald P. Dematteo, Jonathan J. Lewis, Denis H. Y. Leung, Salvinder S. Mudan, James M. Woodruff, Murray F. Brennan

Research Collection School Of Economics

Objective: To analyze the outcome of 200 patients with gastrointestinal stromal tumor (GIST) who were treated at a single institution and followed up prospectively. Summary Background Data: A GIST is a visceral sarcoma that arises from the gastrointestinal tract. Surgical resection is the mainstay of treatment because adjuvant therapy is unproven. Methods: Two hundred patients with malignant GIST were admitted and treated at Memorial Hospital during the past 16 years. Patient, tumor, and treatment variables were analyzed to identify patterns of tumor recurrence and factors that predict survival. Results: Of the 200 patients, 46% had primary disease without metastasis, 47% …


Rearrangement Of The Bcl-6 Gene As A Prognostic Marker In Diffuse Large-Cell Lymphoma, K. Offit, D.C. Louie, N. Z. Parsa, Denis H. Y. Leung, C. Portlock, B.H. Ye, F. Lista, D.A. Filippa, A. Rosenbaum, M. Ladanyi, S. Jhanwar, R. Dalla-Favera, R.S.K. Changanti Jul 1994

Rearrangement Of The Bcl-6 Gene As A Prognostic Marker In Diffuse Large-Cell Lymphoma, K. Offit, D.C. Louie, N. Z. Parsa, Denis H. Y. Leung, C. Portlock, B.H. Ye, F. Lista, D.A. Filippa, A. Rosenbaum, M. Ladanyi, S. Jhanwar, R. Dalla-Favera, R.S.K. Changanti

Research Collection School Of Economics

Current therapy can induce a long-term remission in half the patients with diffuse lymphomas with a large-cell component (DLLC), but more intensive treatment has the potential to improve outcome. Rearrangement of a novel candidate proto-oncogene, bcl-6, correlates with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker.